Researchers at the Center for Life Sciences at the Paul Scherrer Institute PSI have for the first time identified structural ...

Compounding pharmacies aren’t the only makers of off-brand versions of Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound. The ...

With its offering of tirzepatide (branded as Mounjaro and Zepbound), Eli Lilly and Co. (NYSE: LLY) was another key pharma player in this new type of treatment for diabetes and obesity.

Eli Lilly and Co. reported that its FDA-approved weight-loss drug Zepbound (tirzepatide) outperformed Novo Nordisk A/S’s Wegovy (semaglutide) in the phase IIIb Surmount-5 trial.

This hormone slows the rate of how the stomach is emptied and regulates blood sugar. Amycretin also works slightly differently than Eli Lilly’s Zepbound and Viking Therapeutics’ experimental VK-2735, ...

Crucially, CagriSema had been seen as Novo Nordisk’s opportunity to beat Eli Lilly’s Zepbound, which was approved in November 2023 and quickly won market share. Results published in December ...

Today, GLP-1 drugs, including Wegovy, Mounjaro and Zepbound, have become household names and key tools in the fight against obesity: 1 in 8 American adults say they have used a GLP-1 drug ...

This class of drugs, known as glucagon-like peptide-1 receptor agonists, or GLP-1s, also includes Wegovy and Zepbound. GLP-1s were developed to treat diabetes, but they have become popular weight ...

A new generation of obesity drugs – such as Novo Nordisk A/S’ Wegovy and Eli Lilly and Company’s Zepbound – is changing the perception of obesity as a multifaceted illness that requires ...

CLIFTON PARK, N.Y. — Insiya Klapper, who lives in the Capital Region, has experienced a transformative year, shedding 60 pounds with the help of the GLP-1 medication, Zepbound. However ...

1:27 Ozempic can lower chances of multiple health conditions but comes with risks, study finds Ozempic, Wegovy, Zepbound and other drugs often used for weight loss may help lower the risk of a ...

It is the largest study ever of the drug category—which includes Novo Nordisk’s GLP-1 treatments Ozempic and Wegovy and Eli Lilly’s dual-action GLP-1/GIP agonists Mounjaro and Zepbound.